CrystEngComm



PAPER

View Article Online



Cite this: CrystEngComm, 2020, 22,

Optimization and comparison of statistical tools for the prediction of multicomponent forms of a molecule: the antiretroviral nevirapine as a case study†

Rogeria Nunes Costa, (10 ** a Duane Choquesillo-Lazarte, (10 b Silvia Lucía Cuffini, a Elna Pidcock^c and Lourdes Infantes (1)*d

In the pharmaceutical area, to obtain structures with desired properties, one can design and perform a screening of multicomponent forms of a drug. However, there is an infinite number of molecules that can be used as co-formers. Aiming to avoid spending time and money in failed experiments, scientists are always trying to optimize the selection of co-formers with high probability to co-crystallize with the drug. Here, the authors propose the use of statistical tools from the Cambridge Crystallographic Data Centre (CCDC) to select the co-formers to be used in a pharmaceutical screening of new crystal forms of the antiretroviral drug nevirapine (NVP). The H-bond propensity (HBP), coordination values (CV), and molecular complementarity (MC) tools were optimized for multicomponent analysis and a dataset of 450 molecules was ranked by a consensus ranking. The results were compared with CosmoQuick co-crystal prediction results and they were also compared to experimental data to validate the methodology. As a result of the experimental screening, three new co-crystals - NVP-benzoic acid, NVP-3-hydroxybenzoic acid, and NVPgentisic acid – were achieved and the structures are reported. Since each tool assesses a different aspect of supramolecular chemistry, a consensus ranking can be considered a helpful strategy for selecting coformers. At the same time, this type of work proves to be useful for understanding the target molecule and analyzing which tool may exhibit more significance in co-former selection.

Received 1st July 2020, Accepted 28th August 2020

DOI: 10.1039/d0ce00948b

rsc.li/crystengcomm

Introduction

Crystal engineering is an important area of science since it allows one to study and to understand how the arrangement of the atoms and molecules, as well as the intermolecular and intramolecular interactions, will affect the crystalline structure and, consequently, its properties. 1-4 Exploring many aspects of solid-state supramolecular chemistry, crystal engineering is a field of study that could be used to understand a wide variety of materials, such as semiconductors, metalorganic or organic materials, including pharmaceutical compounds. 1,4,5

In the pharmaceutical area, crystal engineering has been intensely explored during the last few years, with the aim to design new forms of pharmaceutical compounds with desired properties, especially, multicomponent forms, such as cocrystals, salts, and solvates.6-8 However, for a complete screening of new multi-component forms of a molecule, e.g., an active pharmaceutical ingredient (API), there is an infinite number of other molecules and solvents that can potentially interact with the target molecule. These molecules and solvents can be called co-former molecules or simply co-formers.

In general, the process adopted for the screening of new forms is 1) identify the functional groups of the target molecule and identify which other groups could interact preferentially, 2) select co-formers containing those functional groups that could interact with the API to form co-crystals, salts and/or solvates of the target molecule, 3) perform the experimental process and identify through solid-state characterization if the new forms were obtained and 4) determine if the desired properties were obtained. As one can imagine, this process could be expensive in terms of time and money. Moreover, one should face the fact that new polymorphs can be found, which increases the number of possibilities.

^a Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo, 12331-280 São Iosé dos Campos, Brazil, E-mail: rogeria.ncosta@gmail.com

^b Laboratorio de Estudios Cristalográficos, IACT, CSIC-Universidad de Granada, Avda. de las Palmeras 4, 18100 Armilla, Granada, Spain

^c Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, UK

^d Instituto de Química Fisica Rocasolano, Consejo Superior de Investigaciones Científicas, 28006, Madrid, Spain. E-mail: xlourdes@iqfr.csic.es

[†] Electronic supplementary information (ESI) available. CCDC 2012053-2012055. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0ce00948b

In order to optimize this cocrystal screening, reducing the number of co-formers to be tested is desirable. A tool capable of reliably predicting which co-formers are most likely to form the multicomponent system with the target molecule is required.

Nowadays, there are some approaches based on different parameters to assess the propensity of a drug and a co-former to co-crystallize. To mention a few, there are computational methods that evaluate the energetic driving force for cocrystal formation;9 methods based on electrostatic potentials of molecular surfaces (MEPS) of both components to estimate the stability of the multicomponent compared to that of the individual molecules;¹⁰ thermodynamic methods COSMOQuick software 11,12 that uses the excess enthalpy of an undercooled melt of a drug and a co-former; and methods based on supramolecular knowledge that evaluate all possible interactions between the target molecule and the co-former and determine if they are robust enough to be preferred against the formation of the individual components.

Therefore, supramolecular knowledge-based tools use the probabilities of formation of intermolecular interactions or the interacting ability of the atoms. In this work, the authors aimed to evaluate the use of three¹³ statistical knowledge-based tools from CCDC for selecting co-formers with a high probability to form new multicomponent forms of the antiretroviral nevirapine (NVP). The named tools are molecular complementarity (MC),14 hydrogen bond propensity (HBP),15 and coordination values (CV), 16-19 available in CSD_Materials. Only MC returns a pass/ fail decision by default, HBP and CV provide likelihoods of hydrogen bond interactions to form, and functional groups to participate in hydrogen bonding, respectively. All three tools have been optimized for a multicomponent analysis. A function that scores the probability of a co-former-API multicomponent formation has been developed for each tool. Based on these scores, the co-formers were ranked from the best to the worst probabilities in each tool. For a combination of the three results, a consensus score was calculated for each of the co-formers as the sum of the position obtained in the three techniques (HBP, CV, and MC). Finally, if the co-formers are ordered by their ascending consensus score, this consensus ranking gives the coformers ordered by their relative potential ability to form a cocrystal with NVP.

The COSMOQuick software 11,12 was also used to evaluate the probability of the selected co-formers to form NVP co-crystals through thermodynamic aspects. The results were added to the consensus ranking. This consensus ranking is a result of the sum of MC, HBP, CV, and COSMOQuick classifications.

Aiming to validate the methodology adopted, experimental procedure to obtain multicomponents was performed with 38 molecules. Since the experimental work was conducted concurrently with the development of the methodology, these co-formers were not selected based on the results of the theoretical screening but represent a selection of molecules readily available to us. Three new co-crystals were found and their structures are reported: NVP-benzoic acid (NVP-BZC), NVP-3-hydroxybenzoic acid (NVP-3HBZC), and NVP-gentisic acid (NVP-GTS) (Fig. 1). These three co-formers are part of a family of carboxyl and hydroxyl substituted benzene compounds, that includes another two compounds, the salicylic acid and the 4-hydroxybenzoic acid, whose cocrystals with NVP have been previously reported. 20,21

Methodology

Selection of co-formers and the generation of appropriate coordinate files for statistical analysis

A dataset of 450 co-formers was selected for this study. All molecules are part of the generally recognised as safe (GRAS) list. Care was taken to include in the list of co-formers all those molecules that appear in the literature as previously tested with NVP and those 38 compounds selected for our experimental work.

The multicomponent analyser tools are provided with molecular geometry and coordinates. Besides, values are dependent on the molecular conformation which is responsible for the chemical group accessibility and also for the molecular shape. The molecular geometry information for the major part of the molecules used in this study is available from the Cambridge Structure Database (CSD). ConQuest v.1.9.0 software was employed to obtain this information for each molecule and by using the Mercury v.3.9.0 software, mol2 files were obtained for each molecule. Mercury tools were used to guarantee that each file exhibits just a single molecule, with no charges, no disorder, and containing all H atoms with bond distances normalized.

In the cases where no information was available in the CSD, mol2 files containing the molecular three-dimensional information were constructed through the Chem3D software (PerkinElmer Informatics).

Molecular conformation can affect calculations for CV and MC. The conformation of a co-former modifies the accessible surface area of the atoms available for the intra- and intermolecular interactions and, consequently, coordination values are affected. Furthermore, the MC tool considers the length of the axes of the virtual box in which the molecule is contained. So, the shape of the molecule could affect this box size and, therefore, the results of the MC. Thus, it was necessary to obtain the most representative conformations for every co-former. All molecules were analysed by the CSD Conformer Generator tool. 22,23 For the rigid molecules, only one conformation was used. However, as the degree of conformational freedom for the co-formers increased, so did the number of molecular conformations

Fig. 1 2D chemical diagram for benzoic acid (BZC), 3-hydroxybenzoic acid (3HBZC), and gentisic acid (GTS).

used as input for the CV and MC tools. Only the best output value was kept for each tool and co-former molecule.

A Python API script was developed to write mol2 files containing the NVP and the co-former molecule. These files were used as input for HBP and CV methods to assess the interactions between the two molecules.

Input for the thermodynamic tool

Paper

The COSMOQuick^{11,12} v.1.7 was used to predict the tendency of cocrystal formation. This tool requires the simplified molecular input line entry specification or SMILES of a molecule as input data. So, the SMILES for the 450 selected molecules were generated using the ChemDraw software (PerkinElmer Informatics).

Multicomponent analysed tools

The three CCDC tools (HBP, CV, and MC) are available in the CSD-materials module in the Mercury package and were modified to be able to evaluate or quantify the stability of a multicomponent *versus* its individual structures. This was achieved by writing bespoke python scripts, utilizing the CSD Python API. After the calculations, for each tool, the co-former molecules were sorted from the best to the worst values. Then, every co-former was assigned a ranking position for each tool. Initially, two consensus scores were calculated. The consensus score A is the sum of HBP, CV, and MC ranking positions; and the consensus score B was calculated by adding the COSMOQuick ranking position to the consensus score A. After the analysis of the results, we considered it necessary to calculate a third consensus classification where the CVs were removed, and it is the consensus score C.

The new structures

A screening of 38 compounds to achieve new cocrystals of NVP was conducted using the liquid-assisted grinding (LAG) method. NVP raw material was manufactured by Nortec Química. Potential co-formers were selected from the GRAS list: acetylsalicylic acid, adipic acid, L-alanine, 4-aminobenzoic acid, L-arginine, L-ascorbic acid, L-aspartic acid, benzamide, benzoic acid, caffeine, catechol, citric acid, L-cystine, fumaric acid, gallic acid, gentisic acid, glutamic acid, 1-glutamine, glutaric acid, glycolic acid, hippuric acid, hydroquinone, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, isonicotinamide, maleic acid, malonic acid, nicotinamide, nicotinic acid, orcinol, oxalic acid, phloroglucinol, resorcinol, succinic acid, theobromine, theophylline, urea, and vanillin. 150 mg of stoichiometric (1:1) amounts of NVP and co-former were ground in the presence of 4 or 5 drops of chloroform. Different milling conditions were applied and they are detailed in the ESI.† Specifically, in the case of NVP-BZC, NVP-3HBZC, and NVP-GTS, the sample mixtures and the solvent were placed in an agate jar with two steel balls (Φ = 5 mm) and milled using the mixer mill MM200 (Retsch), with a vibration frequency of 25 Hz, during 30 minutes. Chloroform was selected because it does not form NVP solvate crystals. All co-formers as well as the chloroform

were at ACS grade. Powder samples were analysed through powder X-ray diffraction (PXRD) to identify the formation of new crystalline phases.

Crystallization and single-crystal X-ray diffraction (SCXRD)

From the screening of 38 molecules, three of them presented a PXRD pattern in agreement with new phases and possible multicomponent forms. Potential co-crystals, NVP-BZC, NVP-3HBZC, and NVP-GTS, were recrystallized in chloroform and ethyl acetate. Single crystals were obtained in both solvents with different quality and the best were selected for a singlediffraction (SCXRD) analysis. X-ray SCXRD experiments for NVP-BZC were performed at room temperature in a Bruker D8 Venture diffractometer (Photon 100 CMOS detector and MoKα radiation from Incoatec micro source), whilst for NVP-3HBZC and NVP-GTS, experiments were conducted in a Bruker D8 Venture diffractometer equipped with a CMOS Photon 100 detector using CuKα radiation at room temperature for the former and at 120 K for the latter. The diffraction images were analysed (indexed, integrated, and scaled) using the Apex3 software.24 Crystal structures were solved through the direct methods and refined by full-matrix-block least-squares in the SHELXL software.25 All non-hydrogen atoms were anisotropically refined, and all hydrogen atoms were placed in idealized geometries according to the riding model. In the three crystal structures, the co-former molecules are situated in the vicinity of a centre of symmetry inducing disorder. Connectivity and rigid body restraints were necessary to describe and refine these fragments.

Methodology validation and generation of ROC curves

Receiver operator characteristic (ROC) curves were obtained to evaluate the performance of the methodology proposed. A ROC curve plots the sensitivity against (1-specificity). The sensitivity is the number of true positive predictions over the total number of positive observations, whilst the specificity is given by the number of false-positive predictions over the total number of negative observations. A binary classifier system was used to correlate predictive and experimental results (Scheme 1) and its discriminative threshold (number of molecules cutoff) varied from low to higher values.

A ROC curve has been obtained for each evaluated tool as well as for the consensus rankings. Besides, the area under curve (AUC) was calculated to evaluate the discriminative

		Experimental res	ults
a		Positive	Negative
Predictive results	Positive	True Positive	False Positive
Δ.	Negative	False Negative	True Negative

Scheme 1 Binary classifier system used to construct ROC curves.

power of each tool. ROC curves and AUC values were obtained using OriginLab software.

Results and discussion

Nevirapine and its multicomponent forms

NVP (11-cyclopropyl-4-methyl-5,11-dihydro-6*H*-dipyrido[3,2-*b*:2',3'-*e*][1,4]diazepin-6-one) (Fig. 2) is an antiretroviral drug used in the treatment of HIV-1 infection.^{26,27} This drug exhibits a low-aqueous solubility and there is interest in improving its solubility through the formation of multicomponent structures.

A total of 76 molecules have been tested to form multicomponent with NVP (Tables 1 and S1†), and depending on the results they were grouped into three clusters: G1 molecules that form multicomponent structures with NVP and are reported in the CSD database or here (highlighted in green), G2 - molecules referred into the literature as forming co-crystals even though their structure is not yet reported (highlighted in yellow), and G3 - molecules that have been but no group has reported multicomponents yet (highlighted in red). The second group also includes the eutectic systems, since, even when the multicomponent structure has not been formed, there are weaker interactions between the two molecules that are responsible for the eutectic behaviour. There are 25 molecules in the first cluster, G1; 17 molecules in the second, G2; and 34 in the third, G3. For the molecules in the groups G2 and G3, a list of the techniques used in the trials are listed in Table S2.†

Groups G1 and G2 have been considered as the positive experimental results while molecules in group G3 are considered as the negative ones.

NVP co-crystals in the literature

There are several multicomponent forms containing NVP that are reported in the literature. Performing a search on the CSD database, nine solvates, ^{28–32} eight co-crystals, ^{20,21,33} and four salts^{34,35} containing the NVP molecule were found, besides the anhydrous^{26,32} and hemihydrate forms^{31,32} (Fig. 3). Also, found was a salt-hydrate structure with pentaiodide and water, ³⁶ and a crystalline inclusion complex. ³⁷

The NVP molecule consists of a 7-membered ring flanked by two rings of aromatic pyridine. The central ring contains a rigid *cis*-amide group which, in most cases, forms a centrosymmetric synthon through a strong amide–amide hydrogen bonding interaction (Fig. 4). Therefore, NVP contains a unique HB-donor atom (the amide NH) and three

Fig. 2 Molecular diagram of nevirapine (NVP).

possible strong HB-acceptor atoms (the amide C=O and the two N in the pyridine rings). Besides, pyridine rings frequently form π - π stacking interactions. Observing the intermolecular potentials calculated around a central NVP molecule for the crystal structure of the anhydrous nevirapine (PABHII) showed that the strongest interaction is due to the π - π stacking interaction between the aromatic rings, followed by the amide-amide homodimer interaction (Fig. 4). Similarly, the full interaction maps (FIMs)^{40,41} generate the interaction landscape of the NVP molecule (Fig. 4) and it suggests that the amide-amide homodimer contact as the preferred interaction. Also, shown (in red, Fig. 4) are the preferred geometries of interaction with the pyridine nitrogens and regions (in brown) parallel to the pyridine rings indicate the possibility for a hydrophobic or π - π interaction. Using this information, we hypothesize that adequate co-formers would be molecules with delocalized double bonds or aromatic rings that can occupy the hydrophobic regions, and/or strong donor-acceptor groups such as carboxylic acids that may disrupt the amide dimer. 16

Investigating the interactions exhibited by the multicomponent structures, the NVP amide-amide homodimer is disrupted only seven times. In four of these, a NVP-co-former heterodimer is formed through amidecarboxylic acid interactions (glutaric acid, maleic acid, tartaric acid, and 4-hydroxybenzoic acid), while in a further two, the homodimer is broken because of a water molecule, and in the remaining one, an amide-amide chain is observed (naphthalene-1,5-disulfonate). In the other structures with available coordinates, the homodimer is maintained. In many cases, a NVP-co-former interaction occurs with the pyridine N. Remarkably, all multicomponent structures exhibit a π - π NVP stacking interaction with just one exception (NVP-naphthalene-1,5-disulfonic acid).

These observations could corroborate our hypothesis that good co-formers must contain carboxylic groups and/or aromatic rings. However, looking at the molecules tested with NVP which have not formed multicomponents, (G3 in Tables 1 and S1†) or which have not been obtained yet, there is a high representation of carboxylic groups and aromatic rings. Therefore, it appears there is not an easy way to predict which molecules will form multicomponent structures.

New co-crystals of NVP

Experimental work to achieve new multicomponent forms of NVP was carried out at the same time that a new method to calculate the propensities of two molecules to crystallize together was developed. From the experimental screening, three molecules were potential candidates to form a NVP-multicomponent. And effectively, we achieve the cocrystallization of NVP-BZC, NVP-3HBZC, and NVP-GTS. The NVP-BZC co-crystal had already been reported as a positive hit in the literature, 42,43 however, its crystalline structure had not been reported yet. Crystals obtained from the recrystallization of NVP and 3HBZC were shown to be a

Table 1 List of all compounds tested with NVP to form multicomponents, grouping in G1, G2 and G3. Ranking positions obtained through the techniques used for all of them are shown. Each group

cacid biote acid biote	CV MC	HBP ranking	Consensus	COSMO	Consensus	Consensus	Tested by	Tested in	OSD refoods
Acid 73 158 33 29 42 oxybenzoic acid 56 85 117 24 32 c acid 22 234 65 126 33 or acid 23 22 234 65 126 30 or acid 23 33 317 225 252 253 20 nor acecia acid* 33 37 201 225 252 26 nor acid 175 23 66 201 273 20 or acid 175 23 13 78 22 20 or acid 175 23 140 60 32 20 or acid 170 27 206 328 21 20 or acid 147 23 144 23 24 36 or acid 140 21 144 23 24 20 or acid 15 14			14 Smmin	Summi	d Simming	Summi		inciacaic	
re acid language aci		c	o c	ç	L	9	>	120,43	1 ATO1120
oxyotations attait c actid actid by 22 234 65 126 134 30 c actid c actid by 33 67 21 279 roacetic actid by 33 67 21 279 roacetic actid c		577	62	25	n ∠	11	7 21	,43	
reacted 109 121 9.0 444 9.0 100 acted 222 234 655 126 134 100 acted 235 322 69 201 100 acted 235 322 69 201 100 acted 236 324 222 200 235 328 222 200 acted 239 124 133 78 291 200 acted 239 124 185 183 246 201 acted 239 124 185 183 246 201 acted 239 124 185 183 246 201 acted 248 371 323 97 292 150 365 acted 240 acted 248 337 202 388 71 110 acted 248 337 202 388 71 156 acted 248 336 328 363 200 acted 248 336 328 363 acted 249 acted 248 336 328 363 acted 250 acted 240 acted 248 336 328 363 acted 250 acte	,	717	† †	200	† 7	1.1	, 21	, 20	I AMOUNT 20 I AMOUNTS and
c acid but		90	44	30	11	13	>	>	LAIQUO, LAIQUOUI, and I ATOIIII02 (ref. 21)
c acid hambers and hambers acid		55	126	134	76	61	*	130	CAT (CO2 (151: 21) OKETH30
racide by the propertie acide by the propertie acide by throughly a part of		67	25	270	7 7	70	ζ >	20,43	I ATOFF ²⁰
Angelent acide introvertial introv		/0	200	6/7	11.0	26	<	3 2	CATCLE OIDMER ³⁵
itrosalicylic acid ^b itrosalicylic acid ^c ic acid ic	723	60	201	10	113	ا ۸		\	QUDWE1
rucosalucylic acid and acid acid acid acid acid acid acid aci	317	225	252	26	155	77		35.	QUDWOD
onl 170 83 153 78 291 ceacid 33 144 110 132 291 ceacid 33 144 164 60 365 xane 371 323 97 292 150 ool 147 29 163 284 365 in 406 377 202 150 365 rin 406 37 202 150 365 rin 406 37 202 150 365 rin 406 37 202 38 71 cid 43 20 20 38 71 cid 43 24 251 156 odobenzene 248 39 444 285 249 reard 247 251 249 249 249 reard 247 251 23 249 reard 248		206	328	22	180	86		, 38 30	QUDWIX
c acid 75 348 110 132 72 cetate 155 40 185 183 246 ol 155 40 163 54 365 wane 371 323 97 292 150 ol 147 29 163 54 386 ol 406 37 202 38 71 rin 406 37 202 38 71 ol 435 293 262 410 69 olobenzene 264 51 427 251 156 olobenzene 264 51 444 285 38 olobenzene 264 51 444 285 38 olobenzene 248 39 444 285 38 olobenzene 248 39 444 285 28 olobenzene 248 38 36 32 28 <td></td> <td>153</td> <td>78</td> <td>291</td> <td>120</td> <td>122</td> <td></td> <td>67,07</td> <td>GIRWUA²² and KACPAH²⁸</td>		153	78	291	120	122		67,07	GIRWUA ²² and KACPAH ²⁸
cetate 339 124 185 183 246 John 164 660 365 wanne 177 29 163 54 386 Irin 140 21 168 48 395 rin 406 37 202 388 71 voidebnezane 264 51 427 251 156 comethane 265 115 444 285 98 romethane 266 115 444 285 98 comethane 268 39 328 363 126 comethane 269 115 444 285 98 comethane 269 116 28 29 comethane 269 118 18 18 18 comethane 269 119 47 comethane 269 249 229 347 147 comethane 269 275 286 289 comethane 269 1164 comethane 269 289 289 comethane 269 cometh		110	132	72	74	126	×	√20 2.0 2.0	$LATRAB^{20}$
bl that the bold of the bold o		185	183	246	198	149	>	√ 31,32	TISJEL ³¹ and TISJEL01 (ref. 32)
wane 371 323 97 292 150 ool 147 29 163 54 386 ool 140 37 168 54 386 rin 406 337 168 38 71 roid 435 293 262 410 69 odobenzene 264 51 427 251 156 comethane 226 115 444 285 98 comethane 226 115 444 285 98 comethane 226 115 444 285 98 cacid 330 336 328 363 126 cacid 52 128 75 23 29 cacid 161 72 31 35 28 oxybenzoic acid 181 162 40 175 oxybenzoic acid 181 123 18 175		164	09	365	138	158	×	√ 28	AKEFEC ²⁸
old 147 29 163 54 386 ol 140 21 168 48 395 rin 406 337 202 388 71 rin 406 337 202 388 71 ricide 435 292 410 69 odoborazene 226 115 444 285 98 Tetrafluoro-3,6-di-iodobenzene 226 115 444 285 98 Tetrafluoro-3,6-di-iodobenzene 248 39 434 231 156 cacid 161 75 444 285 98 cacid 52 45 45 25 249 oxybenzoic acid 64 136 162 62 20 ic acid 181 128 75 23 20 oxybenzoic acid 181 182 18 16 oxybenzoic acid 181 182 18 16 <		26	292	150	223	161		✓32	$ m YIVQUQ^{32}$
140 21 168 48 395 rin 406 337 202 388 71 rin 406 337 202 388 71 roid 435 293 262 410 69 dodobenzene 264 15 447 285 71 romethane 248 39 444 285 71 combedoposenzene 248 39 434 231 249 e 224 75 450 257 212 blact 224 75 450 257 212 cacid 52 36 52 22 22 cacid 41 72 51 52 23 24 cobenzoic acid 181 182 182 40 175 nic acid 181 182 182 40 175 nic acid 183 248 276 40 47 <td></td> <td>163</td> <td>54</td> <td>386</td> <td>139</td> <td>163</td> <td>×</td> <td>✓28</td> <td>AKEFIG²⁸</td>		163	54	386	139	163	×	✓28	AKEFIG ²⁸
rin being 406 337 202 388 71 scidb		168	48	395	137	167	×	✓28	$AKEFOM^{28}$
toid ^b codobenzene 435 293 262 410 69 odobenzene 264 51 427 251 156 comethane 226 115 444 285 98 Tetrafluoro-3,6-di-iodobenzene 248 39 434 231 59 e ^a 224 75 450 257 212 blactam 230 336 328 363 126 cacid 52 128 75 23 126 cacid 64 136 162 62 20 oxybenzoic acid 64 136 162 62 20 oxybenzoic acid 108 81 162 62 20 oxybenzoic acid 181 182 16 40 175 oxybenzoic acid 189 14 76 40 175 oxbenzoic acid 189 14 76 40 175 acid 276 <		202	388	71	274	185	>	✓ ^{20,43}	$LATQOO^{20}$
odobenzene 264 51 427 251 156 romethane 226 115 444 285 98 Tetrafluoro-3,6-di-iodobenzene 248 39 434 231 249 cacid 230 336 328 363 126 cacid cacid 52 128 75 23 coxybenzoic acid 64 136 162 62 20 overland 108 81 38 16 97 cic acid 114 257 189 140 133 cic acid 25 248 305 222 4 cacid 26 69 32 8 330 cacid 26 69 32 8 330 cacid 27 248 305 222 4 cacid 389 249 229 347 147 acid 26 26 27 38 189 140 cacid 389 249 229 347 147 acid 26 27 386 365 222 dylline 38 247 242 165 cacid 389 249 229 347 acid 26 256 386 386 165 cacid 389 249 229 347 acid 26 286 386 286 187 acid 26 301 26 326 187 acid 27 286 386 187 acid 28 287 289 164 acid 28 287 289 164 acid 28 287 288 188 acid 28 287 288 acid 28 2		262	410	69	300	193		✓34	CIKSEV ³⁴
romethane 226 115 444 285 98 Tetrafluoro-3,6-di-iodobenzene 248 39 434 231 249 e ^a 224 75 450 257 212 blactam 230 336 328 363 126 c acid oxybenzoic acid 52 128 75 23 29 coxbenzoic acid 64 136 123 66 67 40 mic acid acid 276 233 138 181 66 acid acid 66 69 32 8 330 lelic acid acid 66 69 32 8 330 lelic acid acid 276 233 138 181 165 acid acid 276 253 141 119 141 119 acid 389 249 229 347 147 acid 296 245 249 249 140 133 c acid 389 249 249 249 140 147 acid 488 247 242 116 acid 548 255 365 422 155 acid 548 257 384 189 164 acid 67 40 174 257 189 140 113 acid 788 247 242 116 264 acid 788 247 242 116 264 acid 68 255 365 422 116 acid 68 265 270 189 164 acid 788 247 242 116 acid 788 247 242 116 acid 88 247 242 116 acid 88 247 242 116 acid 68 265 279 286		427	251	156	202	197		✓33	$RIMWAO^{33}$
Tetrafluoro-3,6-di-iodobenzene 248 389 434 231 249 e ^a 224 75 450 257 212 Jactam 230 336 328 363 126 c acid oxybenzoic acid c acid mic acid mic acid acid ellic acid ellic acid exid acid by 114 257 189 140 c acid c acid c acid c acid c acid c acid ellic acid ell		444	285	86	190	215		✓32	$YIVQIE^{32}$
e ^a 24 75 450 257 212 28 336 328 363 126 c acid oxybenzoic	248	434	231	249	238	255		✓33	$RIMJAB^{33}$
c acid 230 336 328 363 126 2 c acid 161 72 51 35 57 23 29 c acid 64 136 162 62 20 20 c acid 108 81 16 97 40 175 nic acid 181 123 66 67 40 175 nic acid 181 123 18 14 175 175 acid 66 69 33 18 140 175 115 acid 188 270 141 119 47 14 14 47 14		450	257	212	233	267		√ 32	$YIVQOK^{32}$
c acid catid 161 72 51 35 57 oxybenzoic acid 52 128 75 23 29 128 126 162 20 20 100 catid 108 81 181 66 67 40 175 175 181 181 181 181 181 181 181 181 181 18		328	363	126	276	306		✓37	ZEYSAA ³⁷
oxybenzoic acid 64 128 75 23 29 c a c a cid 64 136 162 62 20 20 c a cid 108 81 123 66 67 40 175 e a cid 190 44 76 40 175 a cid 276 233 138 181 181 16 175 a cid 276 278 278 189 140 133 cid 286 229 249 229 347 147 25 384 165 286 299 1644 226 245 245 245 245 245 245 245 245 245 245		51	35	57	6	2	>	$\sqrt{20,42,43}$	
te acid 64 136 162 62 20 tobenzoic acid 108 81 38 16 97 ic acid 181 123 66 67 40 inc acid 276 233 138 181 16 175 acid 66 69 32 8 330 telic acid 153 248 305 222 4 11 c acid 114 257 189 140 133 tcid 389 249 229 347 147 acid 296 275 286 299 164 2 telic acid 389 249 229 347 147 acid 296 275 384 165 187 tele 8 247 242 116 264 11 tele acid 389 249 229 347 147 acid 296 275 36 299 164 2 tele acid 389 249 229 347 147 acid 296 275 384 165 187 tele 308 247 242 116 264 11 tele acid 389 247 242 316 228 228 tele 308 247 242 316 228 228 tele 318 310 228 228		75	23	29	3	6	>		
tic acid to be a cid to be a cid to be a cid to be a cid to acid to ac		162	62	20	21	27	>		
to acid 108 81 38 16 97 ic acid 181 123 66 67 40 nic acid 276 233 138 181 16 acid 276 233 138 181 16 acid 66 69 32 8 330 lelic acid 153 248 305 222 4 1 acid 144 257 189 140 13 1 c acid 389 249 229 34 147 2 acid 174 55 384 165 18 1 acid 296 275 229 164 2 acid 436 225 36 164 2 acid 8 247 242 16 1 acid 8 247 242 16 2 acid 8 247 242<									
ic acid 181 123 66 67 40 nic acid 190 44 76 40 175 acid 276 233 138 181 16 acid 66 69 32 8 330 lelic acid 88 270 141 119 47 acid 153 248 305 222 4 13 ic acid 114 257 189 140 133 1 ic acid 389 249 229 347 147 2 acid 174 55 384 165 187 1 acid 296 275 236 299 164 2 le 436 225 365 422 155 3 le 8 247 242 116 2 2 2 le 203 286 318 310 2 3		38	16	26	7	2	×	✓43	
nic acid 190 44 76 40 175 acid 276 233 138 181 16 acid 66 69 32 8 330 lelic acid 88 270 141 119 47 acid 153 248 305 222 4 13 ic acid 114 257 189 140 133 1 ic acid 389 249 229 347 147 2 acid 174 55 384 165 187 1 acid 296 275 226 299 164 2 acid 436 225 365 422 155 3 ne 436 225 365 422 155 3 namide 8 247 242 116 228 2 16 203 296 318 310 2		99	29	40	26	8	×	\checkmark ²⁰	
acid 276 233 138 181 16 1 acid 66 69 32 8 330 lelic acid 88 270 141 119 47 acid 153 248 305 222 4 1 acid 114 257 189 140 133 1 to acid 389 249 229 347 147 2 acid 256 329 347 147 2 acid 256 275 236 299 164 2 te 436 225 365 422 155 3 te 8 247 242 116 264 1 namide 8 247 242 116 228 2 te 203 318 310 228 2 te 203 280 280 2 2		92	40	175	43	23		✓ ⁴³	
acid 66 69 32 8 330 lelic acid 88 270 141 119 47 acid 153 248 305 222 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		138	181	16	101	44	×	✓43	
lelic acid acid acid acid acid acid acid ac		32	8	330	44	59	×	\checkmark^{20}	
acid 153 248 305 222 4 ce acid 114 257 189 140 133 tcid 96 301 63 98 229 nylline 389 249 229 347 147 acid 174 55 384 165 187 acid 296 275 236 299 164 ne 436 225 365 422 155 namide 8 247 242 155 ne 203 296 318 310 228 ne 203 296 318 310 228 ne 203 279 279 280 236		141	119	47	09	78		✓43	
ceacid 114 257 189 140 133 ccid 96 301 63 98 229 nylline 389 249 229 347 147 acid 174 55 384 165 187 acid 296 275 236 299 164 ne 436 225 365 422 155 namide 8 247 242 116 264 ne 203 296 318 310 228 ne 203 296 379 280 236		305	222	4	130	150	×	✓ ^{20,42,43}	
teid 96 301 63 98 229 hylline 389 249 229 347 147 acid 174 55 384 165 187 acid 296 275 236 299 164 le 436 225 365 422 155 namide 8 247 242 116 264 ne 203 296 318 310 228 le 145 350 279 280 238		189	140	133	116	164	×	√ ^{20,43}	
nylline 389 249 229 347 147 acid 174 55 384 165 187 e 296 275 236 299 164 ne 436 225 365 422 155 namide 8 247 242 116 264 ne 203 296 318 310 228 145 350 279 280 236		63	86	229	114	174	×	√ ⁴³	
acid 174 55 384 165 187 296 275 236 299 164 1e 436 225 365 422 155 namide 8 247 242 116 264 1e 203 296 318 310 228 1e 145 350 279 280 236		229	347	147	272	195	$Eutectic^{21}$	ŝ	
le 436 275 236 299 164 436 225 365 422 155 namide 8 247 242 116 264 1e 203 296 318 310 228 1e 145 350 279 280 236		384	165	187	160	196		√ 20	
ine 436 225 365 422 155 onamide 8 247 242 116 264 line 203 296 318 310 228 116 350 279 280 236		236	299	164	241	227	č	720	
onamide 8 247 242 116 264 line 203 296 318 310 228 145 350 279 280 236		365	422	155	382	272	$Eutectic^{21}$	ŝ	
line 203 296 318 310 228 145 350 279 280 236		242	116	264	152	279		√ ₂₀	
145 350 279 280 236		318	310	228	291	344		√ 20	
		279	280	236	269	357	×	√ ⁴³	
Glutamic acid 85 442 326 335 378 396		326	335	378	396	448	×	\checkmark	

Table 1 (continued)

Oxformer CV MC HBP Consensus CONSMO Consensus Consensus Consensus Consensus Tested in Tested in Tested in 63 CS 113 90 155 64 3 18 18 17 28 18	I able I (confined)										
ranking janking ranking rankin		CV	MC	HBP	Consensus	COSMO	Consensus	Consensus	Tested by	Tested in	
115 90 165 68 17 23 18 X 213 188 143 134 3 61 32 X 213 188 143 134 3 61 32 X 116 173 181 106 5 38 37 X 113 237 197 160 13 12 16 39 45 39 X 113 230 169 128 64 73 81 X 49 291 16 73 48 84 X 45 138 100 34 255 88 89 X 45 138 100 34 255 88 100 108 X 45 138 100 34 255 88 110 108 X 45 138 147 39 76 36 30	Co-former	ranking	ranking	ranking	ranking A	ranking	ranking B	ranking C	our team	literature	CSD refcode
tick of the control o	G3	•									
and the first section of the control	Hydroquinone	115	06	165	89	17	23	18	×		
rid 173 181 106 5 38 37 X rid 137 189 113 9 45 39 X rid 271 230 169 113 124 48 84 88 X 113 231 169 128 64 73 81 X 124 313 86 128 64 73 81 X 49 221 102 91 73 81 X 41 313 86 128 64 73 81 X 44 291 112 324 18 107 34 82 88 110 88 100 89 89 X	Phloroglucinol	213	188	143	134	3	61	32	×		
tick different control of the contro	Resorcinol	116	173	181	106	5	38	37	×		
scid 271 231 31 131 131 137 104 48 X 124 313 86 128 64 73 81 X 124 313 86 128 64 73 81 X 124 291 102 91 75 48 84 X 141 384 18 107 73 89 89 X 45 138 100 34 255 58 96 X 45 138 100 34 255 58 96 X 17 342 77 39 76 56 100 102 X 16 270 147 99 76 56 130 X 17 28 12 26 130 31 31 31 31 31 31 31 32 32 32 32 32	Catechol	137	197	160	113	6	45	39	×		
113 230 169 122 12 52 50 X 449 231 86 128 64 75 841 X 449 449 231 86 128 75 448 841 X X 449 449 431 68 127 75 75 849 841 X X 447 438 410 447 45 435 436 447 447 448 447 448 449 X	Acetylsalicylic acid	271	231	31	131	137	104	48	×		
124 313 86 128 64 73 81 X X	Orcinol	113	230	169	122	12	52	50	×		
49 291 102 91 75 48 84 44 44 44 44 44 4	Glycolic acid	124	313	98	128	64	73	81	×		
141 312 68 127 94 81 87 X 71 384 18 107 139 149	L-Malic acid	49	291	102	91	75	48	84		$\boldsymbol{\chi}^{20}$	
71 384 18 107 73 59 89 X 45 138 138 10 34 255 58 96 X 47 325 138 10 64 102 X 177 345 17 157 88 110 108 X 16 297 147 99 76 56 120 X 260 212 320 290 100 196 130 X 260 212 320 251 64 130 X 260 212 252 51 287 144 36 144 X 274 216 252 51 287 283 149 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 <td< td=""><td>Succinic acid</td><td>141</td><td>312</td><td>89</td><td>127</td><td>94</td><td>81</td><td>87</td><td>×</td><td>$\boldsymbol{\chi}^{20}$</td><td></td></td<>	Succinic acid	141	312	89	127	94	81	87	×	$\boldsymbol{\chi}^{20}$	
45 138 100 34 255 58 96 47 147 147 147 147 147 147 147 147 147 147 147 147 147 144 193 118	L-Tartaric acid	71	384	18	107	73	59	68	×	X ^{20,43}	
47 35 78 79 84 102 102 177 147 147 147 147 147 147 147 147 144	Ferulic acid	45	138	100	34	255	58	96		x ⁴³	
177 342 77 157 88 110 108 x 116 126 120 x 140 147 147 149 140 156 120 x 140	Suberic acid	47	35	78	7	391	64	102		\boldsymbol{x}^{20}	
14 16 297 147 99 76 56 120 X d 358 112 320 290 100 196 130 X l 106 11 22 11 44 93 130 X l 260 21 25 51 88 243 144 <	L-Ascorbic acid	177	342	77	157	88	110	108	×	\boldsymbol{x}^{20}	
(d 358 112 320 290 100 196 130 X 106 1 92 11 444 93 138 X 1e 260 212 277 256 54 162 144 X 1e 8 21 25 51 287 183 190 190 X 4 80 252 85 243 191 209 X e 243 215 287 287 281 289 </td <td>DL-Malic acid</td> <td>16</td> <td>297</td> <td>147</td> <td>66</td> <td>92</td> <td>56</td> <td>120</td> <td>×</td> <td></td> <td></td>	DL-Malic acid	16	297	147	66	92	56	120	×		
106 1 92 11 444 93 138 4 260 212 277 256 54 162 144 4 80 252 51 162 144 7 4 80 252 51 162 190 X 4 82 139 199 209 X e 312 171 187 265 213 209 X e 312 187 265 251 209 X e 423 220 311 395 168 346 241 X side 223 220 311 387 269 269 X side 223 136 268 413 377 286 X social 123 268 413 377 286 X sid 144 263 314 239 426 291 X sid 148 325 424 329 422 424	Nicotinic acid	358	112	320	290	100	196	130	×	$\boldsymbol{\chi}^{20}$	
de 260 212 277 256 54 162 144 4 80 252 51 287 83 190 X 58 17 259 88 243 190 X 6 243 215 259 189 209 209 X 6 312 171 187 265 251 266 X e 312 113 296 228 265 241 X e 423 220 31 387 265 251 266 X side 234 337 287 269 269 X side 263 347 140 266 273 269 X sid 263 264 143 377 286 X sid 140 263 346 149 369 324 X sid 411 325	Stearic acid	106	1	92	11	444	93	138		\boldsymbol{x}^{20}	
le 4 80 252 51 287 83 190 58 117 259 88 243 107 191 X d 243 215 297 265 139 199 209 X e 312 171 187 82 301 131 216 X e 312 113 296 228 265 251 266 X e 423 220 31 395 168 346 243 X ide 234 36 413 37 269 X cadid 25 26 27 26 X cadid 25 27 36 413 37 265 27 sid 14 263 37 266 27 403 X sid 130 411 325 424 239 427 416 X	Orotic acid	260	212	277	256	54	162	144		\boldsymbol{x}^{20}	
the control of the co	Cinnamamide	4	80	252	51	287	83	190		X ₂₀	
d 54 215 297 265 139 199 209 X e 517 187 82 301 131 216 X e 6 312 113 296 228 265 251 226 X e 6 423 220 311 395 168 346 241 X inde 731 131 337 287 257 290 269 X 274 318 263 346 257 269 269 X 2 acid 25 27 268 413 37 269 269 X 2 acid 25 27 268 413 37 269 269 X 3 30 30 30 30 30 30 30 30 30 30 30 30 30	Benzamide	28	117	259	88	243	107	191	×	$\boldsymbol{\chi}_{50}$	
d d 55 171 187 82 301 131 216 X e A23 226 228 265 251 226 X e A23 220 311 395 168 346 241 X inide 319 131 337 287 257 290 269 X 274 318 287 287 287 289 289 X 285 413 346 413 347 348 349 327 348 349 327 349 327 349 328 327 328 328 328 328 328 328 328 328 328 328	Vanillin	243	215	297	265	139	199	209	×		
e 423 220 311 395 265 251 226 X inde 423 220 311 395 168 346 241 X inde 519 131 337 287 269 269 X inde 524 318 263 337 160 273 269 X inde 525 277 346 140 240 240 240 240 240 240 240 240 240 2	Hippuric acid	55	171	187	82	301	131	216	×	★ ^{20,43}	
e 423 220 311 395 168 346 241 X nide 319 131 337 287 257 290 260 X 274 318 263 337 160 273 269 X 408 203 150 268 413 377 286 X 325 277 364 346 140 266 297 X id 130 411 325 344 239 327 403 X cid 301 430 302 423 289 422 424 X 217 438 354 413 323 428 429 437 X 226 429 340 394 328 429 X 327 428 X 328 429 429 X 329 429 424 X 320 424 X 321 432 354 413 325 428 429 X 321 432 433 354 413 354 449 X	Nicotinamide	312	113	296	228	265	251	226	×	$\boldsymbol{\chi}_{50}$	
nide 319 131 337 287 257 290 260 X 274 318 263 337 160 273 269 X 408 203 150 268 413 377 269 X 5 325 277 364 346 140 266 297 X id 14 263 37 169 326 X id 130 411 325 344 239 327 403 cid 301 430 302 423 427 416 X 232 448 338 419 289 422 424 X 217 433 354 413 384 489 X X	Theobromine	423	220	311	395	168	346	241	×		
274 318 263 337 160 273 269 408 203 150 268 413 377 286 X 5 225 277 364 346 140 266 297 X id 14 263 317 156 238 169 304 X id 130 411 325 344 239 327 403 X cid 301 430 302 423 293 427 416 X 232 448 338 419 289 422 424 X 217 433 354 413 323 428 437 X 22 429 340 394 384 449 X	Isonicotinamide	319	131	337	287	257	290	260	×	X ²⁰	
cacid 225 277 364 346 140 266 297	Piperazine	274	318	263	337	160	273	269		X ²⁰	
cacid 225 277 364 346 140 266 297 383 160 270 123 358 186 304 id 14 263 317 156 238 169 326 X cid 130 411 325 344 239 327 403 232 448 338 419 289 422 424 X 217 433 354 413 323 428 439 X	L-Arginine	408	203	150	268	413	377	286	×	$\boldsymbol{\chi}_{50}$	
id id 14 263 317 156 238 186 304 x id 263 317 156 238 169 326 x id 301 301 301 301 301 301 301 302 323 327 403 302 323 427 418 338 419 289 422 428 437 321 438 340 293 394 384 449 x	Pyroglutamic acid	225	277	364	346	140	266	297		\boldsymbol{x}^{20}	
id 14 263 317 156 238 169 326 X cid 130 411 325 344 239 327 403 301 430 302 423 293 427 416 232 448 338 419 289 422 424 X 217 433 354 413 323 428 437 22 429 340 293 394 384 449 X	Succinamide	83	160	270	123	358	186	304		\boldsymbol{x}^{20}	
cid 130 411 325 344 239 327 403 301 430 302 423 293 427 416 232 448 338 419 289 422 424 X 217 433 354 413 323 428 437 22 429 340 293 394 384 449 X	L-Aspartic acid	14	263	317	156	238	169	326	×	\boldsymbol{x}^{20}	
301 430 302 423 293 427 416 x 232 448 338 419 289 422 424 x x 217 433 354 413 323 428 437 x 22 429 340 293 394 384 449 x	DL-Aspartic acid	130	411	325	344	239	327	403		$\boldsymbol{\chi}_{20}$	
232 448 338 419 289 422 424 X 217 433 354 413 323 428 437 22 429 340 293 394 384 449 X	Glycine	301	430	302	423	293	427	416		$\boldsymbol{\chi}_{50}$	
217 433 354 413 323 428 437 22 429 340 293 394 384 449 X	L-Alanine	232	448	338	419	289	422	424	×		
22 429 340 293 394 384 449	L-Valine	217	433	354	413	323	428	437		$\boldsymbol{\chi}_{50}$	
	L-Glutamine	22	429	340	293	394	384	449	×		

^a Toluene does not exhibit donor or acceptor groups. Thus, the HBP and CV ranking positions do not reflect an adequate position. ^b The co-former has suffered deprotonation, resulting in a salt multicomponent form. \star this symbol indicates that two or more groups have tested the co-former, but just one of them has obtained the multicomponent form.




Fig. 3 In the CSD, besides anhydrous and hydrate forms, it was found multi-component structures of NVP with (1) dichloromethane, (2) ethanol, (3) 1-butanol, (4) 1-hexanol, (5) 1-heptanol, (6) 1-octanol, (7) ethyl acetate, (8) 1,4-dioxane, (9) toluene, (10) glutaric acid, (11) maleic acid, (12) tartaric acid, (13) saccharin, (14) salicylic acid, (15) 4-hydroxybenzoic acid, (16) 1,3-diiodobenzene, (17) 1,2,4,5-tetrafluoro-3,6-diiodobenzene, (18) picrate, (19) 3,5-dinitrosalicylate, (20) naphthalene-1,5-disulfonate, (21) trichloro acetate, and (22) ε-caprolactam.

mix of crystals of pure NVP, pure 3HBZC, and the NVP-3HBZC multicomponent.

The crystal structure of the compounds NVP-3HBZ and NVP-GTS are very similar. Both maintain the most frequent




Fig. 4 Representation of the full interaction maps (FIMs) and the intermolecular potentials (kcal mol⁻¹) using the "UNI" force field from a centre molecule of NVP in its crystal structure (PABHIJ).

synthon of amide-amide interaction and the co-formers occupy a centre of symmetry and show disorder, but form a hydrogen bond (HB) between the OH in the carboxylic group (of the co-former) and the nitrogen of the NVP 4-methylpyridine (Fig. 5). Nevirapine molecules pack in the same molecular arrangement in both co-crystals, they are 3D isostructural. Also, their structures are similar to the structure of nevirapine with salicylic acid molecules (CSD refcode LATQUU). The three structures are triclinic $P\bar{1}$ and their unit cell parameter are very similar (Table 2).

NVP-BZC crystallizes in a monoclinic system, P2₁/c. Nevirapine also displays the homodimers and, the benzoic acid molecule forms a hydrogen bond with the nitrogen in the 4-methyl-pyridine. While the co-former disorder is not observed the nevirapine molecules are disordered and present a pseudo plane perpendicular to the molecule that divides it into two halves. This structure is different to all nevirapine compounds observed before because it does not form any $\pi \cdots \pi$ parallel sandwich between pyridine rings. Only for the bis(nevirapinium) naphthalene-1,5-disulfonate salt (CSD refcode QUDWOD), are these NVP-NVP sandwiches replaced by NVP-naphthalene sandwiches. There is another hydroxyl benzoic nevirapine complex, the 4-hydroxy-benzoic acid (CSD refcode POZCOZ).21 This compound crystallizes forming heterodimers between the carboxylic acid and the

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Open Access Article. Published on 03 septembre 2020. Downloaded on 2025-01-25 13:49:36.




Fig. 5 Structures of the compounds (a and d) NVP-BZC, (b and e) NVP-3HBZC and (c and f) NVP-GTS. Hydrogen bonding tetramers showing (a) the NVP disorder and (b and c) the co-formers disorder. On the right a perpendicular view of the crystal structure for (d) NVP-BZC, (e) NVP-3HBZC and (f) NVP-GTS showing in dashed orange lines the $\pi \cdots \pi$ interactions observed in the infinite pyridine stacking of the nevirapine molecules for the compounds NVP-3HBZC and NVP-GTS.

amide chemical groups. This is the only one that disrupts the amide-amide interaction.

As we observed in a previous publication, ²¹ infinite pyridine stacking $(\pi \cdots \pi)$ interactions) of nevirapine molecules displayed

Table 2 Unit cell and secondary structure information for the NVP multicomponents of benzoic acid derivates

Name	Reference CSD-refcode	Space group	a, b, c (Å)	α, β, δ (°)	Volume (ų)	Secondary structure
Benzoic acid	BZC	P2 ₁ /c	9.934(2), 8.360(2), 23.571(6)	90, 92.977(8), 90	1954.9(8)	Amide–amide homodimer
Salicylic acid	LATQUU	$P\bar{1}$	7.1767(4), 9.6278(5), 11.9235(6)	96.865(2), 93.039(2), 98.126(2)	807.69(7)	Amide–amide homodimer
3-Hydroxybenzoic acid	3HBZC	$P\bar{1}$	7.2706(14), 9.5902(19), 11.881(2)	96.11(3), 92.79(3), 98.34(3)	813.3(3)	Amide–amide homodimer
4-Hydroxybenzoic acid	POZCOZ	C2/c	24.318(5), 7.5618(13), 23.242(5)	90, 111.321(8), 90	3981.3(14)	Amide–COOH heterodimer
Gentisic acid	GTS	ΡĪ	7.1010(3), 9.4938(4), 12.0005(5)	95.619(2), 92.881(2), 99.035(2)	793.37(6)	Amide–amide homodimer

Paper

in PABHIJ01 is also conserved in LATQUU (NVP-salicylic acid), POZCOZ (NVP-4-hydroxybenzoic acid), NVP-3HBZC and NVP-GTS cocrystals. While in LATQUU, NVP-3HBZC, and NVP-GTS cocrystals these chains grow into similar 3D structures as we have explained above; in POZCOZ, because of the heterodimers, only these 1D chains are conserved.

Method for statistical evaluation of frequency of interaction for multicomponent prediction

Based on the need for reliable predictive tools to reduce the number of co-formers to be tested, our group has evaluated and proposed a new methodology that modifies the existing tools. Three CCDC tools, H-bond propensity (HBP), coordination values (CV), and molecular complementarity (MC), in addition to the COSMOQuick software, have been used. In each tool, the methodology was applied to 450 coformers and the complete results tables are available in the ESI† (Tables S3–S6). The modifications made and the results obtained are reported below.

Results divided by quartiles

Quartiles division has been used with the goal of helping to explain the results obtained with the four techniques used, and to evaluate the ranking position of the 76 molecules that were attempted experimentally, reported in the literature or presented here; and classified as G1, G2 and G3. The 450 positions in each tool were divided into their quartiles: Q1 goes from position 1 to position 112, Q2 from 113 to 225, Q3 from 226 to 338, and the last one Q4 from 339 to the end. For each quartile, the number of molecules tested with NVP and belonging to each group G1, G2 and G3 have been counted and listed in Table 3.

H-Bond propensity tool

The first tool employed was HBP analysis which evaluates the potential hydrogen bonding landscape for a target system. Although this tool has been available for multicomponent analysis in a previous version of the CSD system, it is now available only for polymorph assessment. This tool identifies all 2D functional group formulas in a system and calculates a propensity index for the formation of the hydrogen bond for all possible combinations of donor and acceptor pairs. The higher the index, the greater the propensity to observe an interaction between the chemical groups involved.

This algorithm involves four stages: (1) data sampling where a search for structures from the CSD containing the same functional groups is performed; (2) extraction of data for the modelling step from structures in the training dataset. The data collected from the training dataset are whether a hydrogen bond exists between particular functional groups, and explanatory variables that include aromaticity, competition and steric density. Logistic regression is used in order to build a model that can predict the likelihood of a hydrogen bond forming given the behaviours observed, and the explanatory variables of the training dataset; (3) model validation, the

logistic regression model is evaluated and is considered good enough to proceed when its area under receiver operating characteristic (ROC) curve is greater than 0.8; and (4) generation and presentation of the results table that contains the HB propensities for each possible donor–acceptor pair in the target structure.

A way to compare the stabilities of a multicomponent (AB) with respect to the structures of each component (A and B) is to compare the propensity index for heteromeric and homomeric interactions. Considering NVP as component A and the co-former as component B, we have identified the highest propensity to form an intermolecular interaction for the pure components (AA or BB) and the multicomponent (AB or BA). The multi-component score is calculated as the difference of the highest propensity (AB or BA) minus the highest propensity (AA or BB). Therefore, the multicomponent HBP score will be greater than zero for those structures with a good chance to co-crystallize, and it will be lower than zero for those systems where pure forms are more likely.

As expected, the co-formers with high multicomponent HBP scores are the ones that, in general, exhibit carboxyl, hydroxyl or sulfhydryl groups (Table S2†). The amino acids appear at the bottom of the table with low HBP values. It is important to note that the HB-pairs that provide the highest HBP scores is not always the HB-network observed in the solid-state of the structures already reported in the CSD. Low propensity interactions found at the expense of better donor-acceptor pairings can be related to a possible risk of polymorphism.⁴⁴

Table 3 Structure distribution by quartiles of the ranking obtained through the different methods employed

A) Co-formers that multicomponent form with NVP has been reported (G1)

	CV	МС	НВР	COSMO		Consensus B	Consensus C
$\overline{Q_1}$	7	10	9	13	11	9	11
Q_2	7	7	10	5	4	11	11
Q_3	6	6	2	4	7	5	3
Q_4	5	2	4	3	3	0	0

B) Co-formers that multicomponent form with NVP has been detected (G2)

	CV	МС	НВР	COSMO		Consensus B	Consensus C
$\overline{Q_1}$	6	4	5	5	5	6	6
Q_2	7	1	3	6	6	5	5
Q_3	2	9	7	5	4	4	3
Q_4	2	2	2	1	2	2	3

C) Co-formers that do not form a multicomponent structure with NVP (G3)

	CV	МС	НВР	COSMO		Consensus B	Consensus C
$\overline{Q_1}$	12	5	9	13	11	17	13
Q_2	11	13	8	5	9	6	8
Q_3	8	9	14	11	8	5	8
Q_4	3	7	3	5	6	6	5

CrystEngComm

Experimental structures show that the amide-amide interaction is disrupted only with carboxylic acid groups or water molecules. There are eight multicomponent structures where the co-former contains a carboxylic acid group, NVPglutaric acid, NVP-maleic acid, NVP-tartaric acid, NVP-4hydroxybenzoic acid, NVP-salicylic acid, NVP-BZC, NVP-3HBZC, and NVP-GTS; HBP in all of these cases provides a heteromeric carboxylic acid-amide interaction as more favourable than homomeric (Table S3†). However, the structures show that only in the first four compounds is this observed and that in the remaining four structures the amide-amide interaction is conserved. The HBP ranking range observed for the co-formers that interrupt the homomeric interaction is (33-117) while for those co-formers that do not break it, are found in the range (51-162).

Coordination values tool

Both HBP and CV calculations were performed using the same functional group definitions. Differently to the HBP tool, the CV tool¹⁹ calculates the likelihood to form 0, 1, 2, 3, 4, 5, and 6 bonds (contacts) by any donor or acceptor atom in a molecule or a target system. These values are derived from a statistical model using the organic structures in the CSD and are dependent on the atom type, the chemical group definition, the Gasteiger charge, 45 the competition among the functional groups in the target system, and the 3D molecular shape that modifies the accessibility to the atoms. From these hydrogen-bond coordination likelihood values is possible to construct a hypothetical hydrogen bond arrangement for a molecule following Etter's rule "the strongest donors tend to interact with the strongest acceptors". 46 However, we want to go further and calculate what we have called the "donor and acceptor capacity" or the ability of a molecule to donate or accept HB contacts. It is defined in eqn (1) and calculates the total number of hydrogen bond contacts participating as either a donor (D) or an acceptor (A) that can form a molecule.

It is expected that the stability of a system would depend on the balance of their donating and accepting ability, e.g., a pure molecule with D = 1.5 and A = 6 would form multicomponent systems easier than a molecule with D = 1.5and A = 2. Because this imbalance is offset by the competition term behind the logic function, we have recalculated the models by removing this parameter from the statistical survey.

$$\begin{split} D &= \sum_{atom_{D},n} \left(like_{n} \times n \right) \\ A &= \sum_{atom_{A},n} \left(like_{n} \times n \right) \end{split} \tag{1}$$

Donor (D) and acceptor (A) capacities. Liken is the likelihood to form n bonds.

Therefore, a multicomponent would be expected to be preferred over its pure forms when the mismatch in its ability to donate and accept HB for the multicomponent system is less than that observed for the individual components. This idea of imbalance was explored before to predict hydration in organic crystals. Some authors⁴⁷ point at a correlation with the donor/acceptor ratio in the organic molecule; however, we observed that while this ratio does not have a significant effect on the frequency of hydrate formation, the sum or the difference of the number of donor and acceptor atoms does.48 It has been quantified in a Coordination Value score (eqn (2)). The lower the CV score, the greater the propensity to obtain a cocrystal.

CV score =
$$|D-A|_{cocrystal} - |D-A|_{NVP} + |D-A|_{cocrystal} - |D-A|_{coformer}$$
 (2)

Calculation of the "comfort" of each pair of NVP and coformer to be together or separated.

The CV distribution, by quartiles, for the observed NVPco-former structures in the CV ranking list is (7, 7, 5, 6) (Table 3A) which can be considered almost random. Furthermore, this distribution for those co-formers tested that do not form multicomponents is (12, 11, 8, 3) (Table 3C) showing an opposite trend to that expected.

Looking at the 112 structures of the first quartile in CV ranking in Table S4,† 25 molecules have been tested with NVP in experimental trials (Table 3). Half of them, thirteen molecules, have resulted in a multicomponent form with NVP, although their crystalline structure has been reported in only seven cases. The only observed cocrystal in the first 50 structures is the propionamide molecule that appears at position 8. On the other hand, among the twelve molecules that have not resulted in a multicomponent form with NVP, seven co-formers are found in the fifty highest ranked coformers. The structures presented here NVP-BZC, NVP-3HBZC, and NVP-GTS are situated in CV positions of 161, 52, and 64, respectively, and the other hydroxyl derivates of the benzoic display positions of 109 for the NVP-salicylic acid and 56 for NVP-4-hydroxybenzoic acid.

Molecular complementarity tool

Developed by Fábián, 14 it is a method to assess the likelihood of two molecules to form a co-crystal based on the shape and polarity of the molecules through the comparison of five molecular descriptors: M axis over L axis, S axis, S axis over L axis, dipole moment, and the fraction of N and O atoms over the total number of atoms in the molecule. S, M, and L are the short, medium, and long dimensions of a box that enclosed the van der Waals surface of the molecule and represent the dimensions of the molecule. Based on the observation that molecules that co-crystallize tend to have similar molecular properties, 14 Fábián defined threshold values for the five molecular descriptors and, any molecule that differs from the target molecule outside the threshold, will be unlikely to co-crystallize with it. Three of the descriptors are based on the molecular shape, and are directly related to the molecular conformation. We have observed the case of the NVP-salicylic acid co-crystal.²¹ In

this case, the MC result is dependent on a simple rotation in the H atom from the carboxylic group that can alter the S axis of the molecule and the molecule can either fail or pass.

The NVP molecule exhibits the following values for each descriptor: M/L axes = 0.895, S axis = 6.667 Å, S/L axes = 0.611, $\mu = 1.972$, and % of N and O = 0.25 (Table S5†). In our screening of 450 co-formers, the majority of the molecules that do not pass the molecular complementarity failed because the dimension of their box does not fit the ranges required for the descriptors (0.585 < axis ratio M/L < 1.0), (3.437 < S axis < 9.897), and (0.336 < axis ratio S/L < 1.0). This is the case, for example, of planar molecules (S axis too small) and molecules that contain a large aliphatic chain (L axis more than 1.7 times the M axis).

From the 25 NVP-co-former structures known, 11 fail the MC screening because of their box dimension descriptors, except the picric and tartaric acids which fail based on the percentage of N and O atoms.

To have a score and a ranking to add to the previously calculated HBP and CV scores, we need something else than a PASS/FAIL test. That is why we have proposed the normalization function in eqn (3). It uses the values calculated by the MC tool for each descriptor and the preestablished limits for the PASS/FAIL result. The lower the MC index, the more similar or complementary the pair of molecules are; and therefore, the greater the propensity to form a multicomponent.

$$MC = \frac{\Delta M/L}{0.31} + \frac{\Delta S}{3.23} + \frac{\Delta S/L}{0.275}$$

$$+ \frac{\Delta dipole\ moment}{5.94} + \frac{\Delta fraction_N_O}{0.294}$$
(3)

Normalization equation to calculate the MC score for each molecule.

Many of the molecules in our screening of 450 co-formers that fail because of their size parameters, using the MC as implemented in the Mercury program are at the top of the list when sorted by their MC ranking; and molecules at the bottom fail because the difference in the dipole moment value (Table S5†). Moreover, from the 25 NVP-co-former structures known, using the score obtained with the equation defined here, the fourteen molecules that pass the PASS/FAIL test got MC scores distributed by quartiles of (4, 5, 4, 1) and those that fail were distributed over the quartiles as follows (6, 2, 2, 1) and the ones that fail in the percentage of N and O atoms are those which obtain the worst MC scores (Table 3).

According to Fábián theory, 14 if a molecule fails in at least one of the descriptors, it is possible to assume that this molecule will not form a multicomponent structure with the API. 44% of the structures reported for NVP multicomponents fail at least in one of the categories of descriptor. However, the MC score values obtained with our normalization function display good values for those molecules that fail the test but form multicomponent of NVP. Based on these observations, it is likely that the thresholds will need to be readjusted to make the three molecular descriptors based on the shape of the molecule more permissible.

COSMOQuick

The COSMOQuick tool¹¹ is used to predict the tendency of cocrystal formation by calculating the excess enthalpy of formation (H_{ex}) between NVP and the corresponding coformer relative to the pure components in a supercooled liquid phase. $H_{\rm ex}$ is a rough approximation of the free energy of cocrystal formation $\Delta G_{\text{cocrystal}}$. Compounds with $H_{\text{ex}} < 0$ show an increased probability of forming cocrystals.

The COSMOQuick approach is based on the COSMO-RS theory. In the COSMO-RS theory, 49,50 the σ -profile of a molecule can be calculated from a combination of σ -profile of different molecular fragments. Since this information, calculated from COSMO theory, is stored in a database, and due to a rigorous statistic, a consistent thermodynamic

Table 4 Ranking positions for co-formers of the benzoic acid derivates and the hydroxyl compound that were tested with NVP. The X symbol indicates that the co-former was tested but the multicomponent form was not obtained, whereas the 🗸 symbol indicates that the multicomponent was obtained

Co-former	CV ranking	MC ranking	HBP ranking	Consensus ranking A	COSMO ranking	Consensus ranking B	Consensus ranking C	Tested by our team	Tested in literature	Molecular formula
Benzoic acid	161	72	51	35	57	9	2	✓	✓ ^{20,42,43}	$C_7H_6O_2$
Salicylic acid	109	121	90	44	30	11	13	\checkmark^{21}	\checkmark^{20}	$C_7H_6O_3$
3-Hydroxybenzoic acid	52	128	75	23	29	3	9	✓		$C_7H_6O_3$
4-Hydroxybenzoic acid	56	85	117	24	32	4	11	\checkmark^{21}	\checkmark^{43}	$C_7H_6O_3$
Gentisic acid	64	136	162	62	20	21	27	✓		$C_7H_6O_4$
2,4-Dihydroxybenzoic acid	65	114	14	10	15	1	1			$C_7H_6O_4$
Gallic acid	276	233	138	181	16	101	44			$C_7H_6O_5$
Phenol	17	120	227	65	23	22	42			$C_6H_6O_1$
Catechol	137	197	160	113	9	45	39	X		$C_6H_6O_2$
Resorcinol	116	173	181	106	5	38	37	X		$C_6H_6O_2$
Hydroquinone	115	90	165	68	17	23	18	X		$C_6H_6O_2$
Phloroglucinol	213	188	143	134	3	61	32	X		$C_6H_6O_3$

Consensus ranking A is obtained by the sum of CV, MC, and HBP ranking positions. Consensus ranking B resulted by the addition of COSMO ranking position to the consensus ranking A. Consensus ranking C is obtained adding the ranking positions in MC, HBP, and COSMO rankings.

CrystEngComm Paper

approximation can be obtained. Thus, the chemical potential and the free energy of a compound, as well as other physicochemical properties can be easily obtained.

Although the results are calculated over the excess enthalpy (H_{ex}) of formation, the ranking is obtained over the function f_{fit} . The f_{fit} function is dependent on the H_{ex} value, but also takes into account the number of rotatable bonds in the molecules. 12 Thus, the ranking according to $f_{\rm fit}$ gives improved results even if the co-former molecules have different numbers of rotatable bonds.12

The results obtained by COSMOQuick shown that there is a preference for NVP to co-crystallize with co-formers that exhibit hydroxyl and carboxyl functional groups (Table S6†). On the other hand, molecules that exhibit amide groups and the saccharides are those with less chance to co-crystallize with NVP, according to the thermodynamic calculation performed by COSMOQuick. This is an unexpected result, since the NVP itself exhibits an amide group, and it is expected that other amide groups could easily interact with it.

The distribution of the molecules for the 25 observed NVP-co-former structures by quartiles based on the COSMO ranking is (13, 5, 4, 3) (Table 3A) which is excellent if it was not similar to the distribution observed for those co-formers that do not form multicomponents (13, 5, 11, 5) (Table 3C). It that molecules containing aromatic rings substituted with -OH groups, e.g., phenol, catechol, resorcinol, and hydroquinone exhibit a good prediction to cocrystallize with NVP, according to COSMOQuick analysis (Tables 4 and S6†). However, after many tries to co-crystallize these co-formers with NVP, it was not possible to obtain these multicomponent forms. On the other hand, their equivalent molecules substituted with carboxyl and hydroxyl groups, benzoic acid, salicylic acid, 3-hydroxybenzoic acid, and 4-hydroxybenzoic acid could be co-crystallized with NVP, even though they obtained lower COSMOQuick rankings.

Consensus ranking

In each tool - HBP, CV, MC, and COSMOQuick - rankings of co-formers were obtained where the co-formers were ordered from the best to the worst probabilities to interact with the NVP molecule. Aiming to establish a unique result to assess the likelihood to obtain a multicomponent form of NVP, three different consensus rankings were calculated.

These consensus rankings were generated from the sum of the positions in each of the rankings. The first consensus, or consensus ranking A, was obtained from the sum of the positions in HBP, CV, and MC rankings (Table S7†). The consensus ranking B was calculated adding to the consensus ranking A the position obtained in the COSMOQuick ranking (Table S7†). Due to the random values obtained for CV, a third consensus ranking was calculated omitting these values (HBP + MC + COSMO).

Thus, the co-formers were ordered from the highest to the lowest probabilities to form a multicomponent structure with the NVP. Examination of the distribution of the molecules

tested by quartiles (Table 3) consensus ranking C seemed to be the most adequate for co-crystallization prediction.

Co-crystals of NVP with hydroxyl derivates of benzoic and phenol molecules

In the CSD there is recorded two multicomponents of NVP with benzoic acid derivatives (LATQUU and POZCOZ); and we are reporting in this manuscript two new structures, NVP-3HBZC and NVP-GTS besides the NVP-BZC structure.

These five structures form a group of hydroxyl derivatives of benzoic acid. In order to probe the predictions, we have included in our experimental and theoretical work equivalent hydroxyl derivatives of the phenol molecule (Table 4): benzoic acid vs. phenol, salicylic acid vs. catechol, 3-hydroxybenzoic acid vs. resorcinol, 4-hydroxybenzoic acid vs. hydroquinone, and one more, phloroglucinol. While the five carboxylic acid compounds formed the multicomponent with experimental techniques used, none of the hydroxyl compounds gave a different phase in our experiments.

Although all three statistical methods (HBP, CV, and MC) show better results for benzoic derivatives than for phenol derivatives, their values are distributed up to position 161 (reached with the CV's position for benzoic acid, NVP-BZC) of the 450 co-formers verified. With COSMOQuick, all these co-formers scored well in the first 57 positions, with hydroxyl compounds scoring better than the equivalent carboxylic acid derivatives (Table 4). With consensus ranking C, the carboxylic acid derivates are in the range (2-27) and the hydroxyl compound appears in the range (18-42).

Methodology validation

To validate the methodology used here is necessary to assembly all the information available in the literature concerning the attempts to find multicomponent forms of NVP in addition to the experiments realized in this work (Tables 1 and S1†). As we have explained before, a total of 76 molecules were tested to form multicomponent with NVP, and depending on the results they were grouped into three clusters, G1, G2 and G3.

To evaluate the ranking position of the molecules that were attempted experimentally, the 450 positions in each tool (Table S7†) were divided into their quartiles. For each quartile, the number of molecules tested with NVP and belonging to each group G1, G2 and G3 have been counted and are shown in Table 3. For molecules in group G1, as was expected, there is a preference for the first and second quartiles for all the methods and the three consensus scores with exception of the distribution observed in the CV. The opposite tendency would be expected for the molecules in G3; however, while there is more representation of molecules in quartile Q4 the maximum is still in Q1 for all the methods. Therefore, it appears that the methods employed are not sufficiently discriminatory. Our opinion is that all the molecules selected to test with NVP have not been selected at random, and have been chosen with characteristics that

Paper

suggest cocrystal formation is likely. And either they will never cocrystallize with NVP or their cocrystals have not been found yet. Table S8† contains the number and frequency of molecules containing some of the most frequent chemical groups in both samples: the 76 molecules tested to form multicomponents with NVP and the dataset of 450 molecules used in the theoretical screening. This distribution shows that the molecules selected to perform the NVP cocrystallization tests preferably have carboxyl and amide groups with a reduction of other common groups such as primary amine or hydroxyl. A higher phenyl ring frequency is also observed.

COSMO with 13 molecules of G1 in quartile Q1 could be identified as the best result but this method also presents the highest number of false positives with 13 molecules belonging to the group G3 also in quartile Q1.

Of the three consensuses ranking calculated, consensus C display the highest capacity for separation.

The performance of the methodology has been also evaluated by ROC curves. The "positive experimental results" include molecules in the groups G1 (green) and G2 (yellow) minus those in which we were unable to reproduce the multicomponents (Tables 1 and S1†). The "negative experimental results" included all molecules from G3 (red). ROC curves for each tool as well as for the consensus rankings A B and C were obtained (Fig. S1†). The overall performance was measured by the area under the curve (AUC) which gives a measure of the separability between classes. The higher the AUC, the better the predictive model is. AUC value must be higher than 0.5; if it is 0.5 the model has no discriminatory capacity. The AUC calculated for the ROC curves for HBP, CV, MC and COSMO are 0.56, 0.42, 0.65 and 0.59 respectively, and for the consensus A, B and C are 0.56, 0.56 and 0.62 respectively (Fig. S1†). According to these values MC has 65% chance to determine which molecules will form a multicomponent with NVP. Consensus C with 62% of predictive capacity (Fig. 6) improves compared to the other two consensuses. CV has an AUC of 0.42 what means that the model is not able to distinguish between positive and negative hits, it gives a random prediction.




Fig. 6 ROC curve for consensus ranking C.

Conclusions

No one doubts that relationships exist between structure and function or structure and properties. This is the reason why great efforts are made trying to predict the structure of a molecule in its crystalline solid-state. However, the prediction of how a molecule will crystallize, or if it will exhibit polymorphs, whether it will form a hydrate, a solvate, a cocrystal, or in general, a multiple form, is not straightforward. Besides, for some molecular systems, it is quite complex.

The present work has proposed a way to combine different tools aiming increase the strength of all of them individually. Even when the results are not very discriminatory, it is clear that MC, HBP and COSMO are as good as they are bad. None of them seems better than the other while the function developed to use CV scores generates what seems random results.

The strategy to combine results in a consensus ranking from different methods has been shown to have some utility, returning results that are more reliable. Furthermore, the new normalized function applied to the descriptors defined by Fábián in the molecular complementarity tool has resulted the best method for ordering the potential co-formers of nevirapine, based on the area under the ROC curve of 0.65.

The method used in HBP to evaluate multicomponents only uses the strongest interaction in the multicomponent (AB or BA) and the strongest contact in each component (AA or BB). The results obtained here show that a new strategy including more interactions could improve this method.

Experimentally, three new crystal structures (NVP-BZC, NVP-3HBZC, NVP-GTS) have been reported and further characterization of these co-crystals is underway and will be presented in future work. These three co-formers were the only ones that formed a new phase from a screening of 38 molecules and it corroborates our observation that NVP is likely to cocrystallize with molecules that contain carboxylic acid groups and aromaticity. However, the fact that none of the tools or its combinations were capable of identifying the negative hits is quite interesting and an explanation of this observation is attempted. First, we should keep in mind that, although these molecules have not formed multicomponent structures with NVP, with the LAG method, they may be obtained in the future by another method. Moreover, the thirteen molecules from group G3 (no cocrystals formed) that appear in quartile Q1 (predicted as good candidates to form multicomponents) by consensus C, are: suberic acid, malic acid, succinic acid, L-ascorbic acid, L-tartaric acid, ferulic acid, hydroquinone, resorcinol, phloroglucinol, catechol, orcinol, acetylsalicylic acid, and glycolic acid. It is possible to imply that all these molecules have been chosen following the criteria that they all have -OH and/or -COOH groups. Besides, some of them are, also, aromatic. That is, they had not been chosen randomly but the possible interactions with the NVP molecule were considered.

In addition all NVP structures indicate that the π - π interactions are important in NVP crystal packing; and probably none of the methods used adequately considers the stacking of

molecules in their predictions of intermolecular interactions. Even the COSMO analysis, which considered the chemical potentials, is not capable to evaluate directly the impact of the aromatic rings in the multicomponent formation.

Thus, we could conclude that the characteristics of the API affected the methodology proposed. However, although the results were not as good as expected, our group considers that it is worth putting an effort to test this methodology in some other systems. And we would like to check the methods without bias in the selection of the co-formers, using molecules with the full range of characteristics in the experimental screening.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was conducted during scholarship supported by the Consejo Superior de Investigaciones Científicas (CSIC) (COOPA20094) and Red de Cristalografía y Cristalización "Factoría de Cristalización" (FIS2015-71928-REDC, MCIU). R. N. Costa would like to thank the support offered by CCDC during her stay in Cambridge as well as Richard Sykes for his support in the development of Python API scripts. This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. D. Ch.-L. acknowledges funding by project no. PGC2018-102047-B-I00 (MCIU/AEI/FEDER, UE). R. N. Costa thanks CAPES for the Ph.D. scholarship. R. N. Costa would like to thank the support offered by Luana P. Meleiro in the obtention of ROC curves.

Notes and references

- 1 D. Braga, Chem. Commun., 2003, 2751-2754.
- 2 A. Mukherjee, Cryst. Growth Des., 2015, 15, 3076–3085.
- 3 G. R. Desiraju, J. Chem. Sci., 2010, 122, 667-675.
- 4 G. R. Desiraju, J. Am. Chem. Soc., 2013, 135, 9952-9967.
- 5 G. R. Desiraju, Crystal Design: Structure and Function -Perspectives in Supramolecular Chemistry, John Wiley & Sons, Hyderabad, India, 2003, vol. 7.
- 6 S. Domingos, V. André, S. Quaresma, I. C. B. Martins, M. F. M. da Piedade and M. T. Duarte, J. Pharm. Pharmacol., 2015, 67, 830-846.
- 7 J. Aaltonen, M. Allesø, S. Mirza, V. Koradia, K. C. Gordon and J. Rantanen, Eur. J. Pharm. Biopharm., 2009, 71, 23-37.
- 8 N. Blagden, M. de Matas, P. T. Gavan and P. York, Adv. Drug Delivery Rev., 2007, 59, 617-630.
- 9 C. R. Taylor and G. M. Day, Cryst. Growth Des., 2018, 18, 892-904.
- 10 T. Grecu, C. A. Hunter, E. J. Gardiner and J. F. McCabe, Cryst. Growth Des., 2014, 14, 165-171.
- 11 Y. A. Abramov, C. Loschen and A. Klamt, J. Pharm. Sci., 2012, 101, 3687-3697.
- 12 C. Loschen and A. Klamt, J. Pharm. Pharmacol., 2015, 67,

- 13 C. R. Groom, I. J. Bruno, M. P. Lightfoot and S. C. Ward, Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater., 2016, 72, 171-179.
- 14 L. Fábián, Cryst. Growth Des., 2009, 9, 1436-1443.
- 15 P. T. A. Galek, L. Fábián, W. D. S. Motherwell, F. H. Allen and N. Feeder, Acta Crystallogr., Sect. B: Struct. Sci., 2007, 63, 768-782.
- 16 L. Infantes and W. D. S. Motherwell, Z. Kristallogr., 2005, 220, 333-339.
- 17 L. Infantes and W. D. S. Motherwell, Chem. Commun., 2004, 1166-1167.
- 18 J. Chisholm, E. Pidcock, J. van de Streek, L. Infantes, S. Motherwell and F. H. Allen, CrystEngComm, 2006, 8, 11-28.
- 19 P. T. A. Galek, J. A. Chisholm, E. Pidcock and P. A. Wood, Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater., 2014, 70, 91-105.
- 20 M. R. Caira, S. A. Bourne, H. Samsodien, E. Engel, W. Liebenberg, N. Stieger and M. Aucamp, CrystEngComm, 2012, 14, 2541-2551.
- 21 R. N. Costa, A. L. Reviglio, S. Siedler, S. G. Cardoso, Y. G. Linck, G. A. Monti, A. M. G. Carvalho, J. A. L. C. Resende, M. H. C. Chaves, H. V. A. Rocha, D. Choquesillo-Lazarte, L. Infantes and S. L. Cuffini, Cryst. Growth Des., 2020, 20, 688-698.
- 22 R. Taylor, J. Cole, O. Korb and P. McCabe, J. Chem. Inf. Model., 2014, 54, 2500-2514.
- 23 J. C. Cole, O. Korb, P. McCabe, M. G. Read and R. Taylor, J. Chem. Inf. Model., 2018, 58, 615-629.
- 24 Bruker, 2016.
- 25 G. M. Sheldrick, Acta Crystallogr., Sect. C: Struct. Chem., 2015, 71, 3-8.
- 26 P. W. Mui, S. P. Jacober, K. D. Hargrave and J. Adams, J. Med. Chem., 1992, 35, 201-202.
- 27 E. De Clercq, Int. J. Antimicrob. Agents, 2009, 33, 307-320.
- 28 N. Stieger, W. Liebenberg, J. C. Wessels, H. Samsodien and M. R. Caira, Struct. Chem., 2010, 21, 771-777.
- 29 C. C. P. da Silva, S. L. Cuffini, S. N. Faudone, A. P. Ayala and J. Ellena, Acta Crystallogr., Sect. E: Struct. Rep. Online, 2008, 64, 0292.
- 30 N. Stieger, M. R. Caira, W. Liebenberg, L. R. Tiedt, J. C. Wessels and M. M. De Villiers, Cryst. Growth Des., 2010, 10, 3859-3868.
- 31 B. G. Pereira, F. D. Fonte-Boa, J. A. L. C. Resende, C. B. Pinheiro, N. G. Fernandes, M. I. Yoshida and C. D. Vianna-Soares, Cryst. Growth Des., 2007, 7, 2016-2023.
- 32 M. R. Caira, N. Stieger, W. Liebenberg, M. M. De Villiers and H. Samsodien, Cryst. Growth Des., 2008, 8, 17-23.
- 33 M. A. Kryukova, A. V. Sapegin, A. S. Novikov, M. Krasavin and D. M. Ivanov, Crystals, 2019, 9, 71.
- 34 W. T. A. Harrison, T. V. Sreevidya, B. Narayana, B. K. Sarojini and H. S. Yathirajan, Acta Crystallogr., Sect. E: Struct. Rep. Online, 2007, 63, 03871.
- 35 S. Jin, H. Zhang, K. Xu, X. Ye, Y. Fang, Y. Zhang, L. Jin and D. Wang, J. Chem. Crystallogr., 2015, 45, 213-223.
- 36 M. A. Kryukova, A. V. Sapegin, A. S. Novikov, M. Krasavin and D. M. Ivanov, Z. Kristallogr., 2019, 234, 101-108.

Paper

37 X. Yang, B. Yu, Z. Zhong, B. Guo and Y. Huang, *Int. J. Pharm.*, 2018, 543, 121–129.

- 38 A. Gavezzotti and G. Filippini, *J. Phys. Chem.*, 1994, **98**, 4831–4837.
- 39 A. Gavezzotti, Acc. Chem. Res., 1994, 27, 309-314.
- 40 I. J. Bruno, J. C. Cole, J. P. M. Lommerse, R. S. Rowland, R. Taylor and M. L. Verdonk, *J. Comput.-Aided Mol. Des.*, 1997, 11, 525–537.
- 41 P. A. Wood, T. S. G. Olsson, J. C. Cole, S. J. Cottrell, N. Feeder, P. T. A. Galek, C. R. Groom and E. Pidcock, *CrystEngComm*, 2013, **15**, 65–72.
- 42 P. P. Gujar, A. A. Kokil, P. S. Karekar, Y. A. Gurav and A. V. Yadav, *Int. J. Pharm. Technol.*, 2013, 4, 4831–4842.

- 43 Y. K. Nalte, V. A. Arsul, S. G. Shep and S. B. Bothara, J. Pharm. Res., 2015, 9, 556–561.
- 44 P. T. A. Galek, F. H. Allen, L. Fábián and N. Feeder, *CrystEngComm*, 2009, **11**, 2634–2639.
- 45 J. Gasteiger and M. Marsili, Tetrahedron, 1980, 36, 3219-3228.
- 46 M. C. Etter, Acc. Chem. Res., 1990, 23, 120-126.
- 47 G. R. Desiraju, J. Chem. Soc., Chem. Commun., 1991, 426-428.
- 48 L. Infantes, L. Fábián and W. D. S. Motherwell, *CrystEngComm*, 2007, **9**, 65–71.
- 49 A. Klamt, COSMO-RS from Quantum Chemistry to Fluid Phase Thermodynamics ad Drug Design, Elsevier, Amsterdam, 2005.
- 50 A. Klamt, V. Jonas, T. Bürguer and J. C. W. Lohrenz, J. Phys. Chem., 1998, 102, 5074–5085.